{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:43:27Z","timestamp":1793119407868,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The orally available toll-like receptor 7 (TLR7) agonist prodrug RO7119929 is converted to active drug predominantly in the liver, where it is hypothesized to reprogram the local immune microenvironment. We aimed to explore the safety, pharmacokinetics (PK), and preliminary antitumor activity and obtain the proof-of-mechanism for RO7119929 in patients with liver cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RO7119929 was investigated in mouse tumors and liver tissue from cynomolgus monkeys. In the first-in-human, open-label, dose-escalation and expansion study, patients with histologically confirmed advanced or metastatic primary liver cancers or solid tumors with predominant liver involvement received RO7119929 weekly in 3-week cycles either on a flat-dose (FD) or step-up dose (SUD) schedule.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Preclinical results demonstrated antitumor activity and the proinflammatory proof-of-mechanism in mouse liver tumors and cynomolgus monkey liver tissue. The subsequent first-in-human study enrolled 27\u2009patients in five FD dose-escalation cohorts, 18\u2009patients in a FD dose-expansion cohort, and 9\u2009patients in two SUD dose-escalation cohorts. The most common primary tumor type at study entry was hepatocellular carcinoma (HCC) (31%). PK data showed fast conversion of RO7119929 to the active TLR7 agonist. Treatment-related adverse events (TRAEs) were observed in 50 (91%) patients across all treated patients; the most commonly reported TRAE was cytokine release syndrome (CRS) in 48 (81%) patients. CRS was also identified as a dose-limiting safety risk and had a dose-dependent incidence and severity. Grade 3 CRS occurred in six (13%) patients receiving FD RO7119929, while no grade 3 CRS was reported in SUD patients at comparable target dose levels. TLR7-related transient, dose-dependent gene expression and cytokine induction was observed both with FD and SUD treatment and corresponded with treatment-induced local inflammation of the tumor microenvironment induced by reprogramming of the myeloid cells. Among 17\u2009patients with HCC, one durable complete response was observed, and 10 (59%) patients had stable disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SUD appears to reduce the risk of CRS while maintaining mode-of-action-relevant pharmacodynamic effects. The clinical activity of RO7119929 as a single agent was limited, suggesting that combination therapy with a checkpoint inhibitor may be needed to leverage the proinflammatory potential of RO7119929 and further increase antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04338685\">NCT04338685<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012783","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:40:25Z","timestamp":1773067225000},"page":"e012783","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04338685","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Changhoon","family":"Yoo","sequence":"first","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Fabregat-Franco","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5789","authenticated-orcid":false,"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Qvortrup","sequence":"additional","affiliation":[{"name":"Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea (the Republic of)"},{"name":"Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Jongno-gu, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[{"name":"Medicine, Queen Mary Hospital, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Don","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Castet","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-729X","authenticated-orcid":false,"given":"Mariano","family":"Ponz Sarvise","sequence":"additional","affiliation":[{"name":"HPB Oncology Area, Cancer Center Cl\u00ednica Universidad de Navarra and CIMA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-9003","authenticated-orcid":false,"given":"Kristoffer Staal","family":"Rohrberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Sebastian","family":"Lichtenegger","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1168-8348","authenticated-orcid":false,"given":"Izolda","family":"Franjkovic","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH Penzberg, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A","family":"Kratochwil","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bessa","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rossmann","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-8095","authenticated-orcid":false,"given":"Petra C","family":"Schwalie","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Rieder","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-0424","authenticated-orcid":false,"given":"Thomas","family":"P\u00f6schinger","sequence":"additional","affiliation":[{"name":"Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Godfried","family":"Sie","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Dettling","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Schlenker","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congqi","family":"Dai","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yun","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Hall","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Yeo Te-Ying","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hoves","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Cannarile","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schiff","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[{"name":"HPB Oncology Area, Cancer Center Cl\u00ednica Universidad de Navarra and CIBEREHD, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026030907401624000_14.3.e012783.1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026030907401624000_14.3.e012783.2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000966","article-title":"T-cell agonists in cancer immunotherapy","volume":"8","author":"Choi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026030907401624000_14.3.e012783.3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680"},{"key":"2026030907401624000_14.3.e012783.4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00304","article-title":"Anti-tumor Activity of Toll-Like Receptor 7 Agonists","volume":"8","author":"Chi","year":"2017","journal-title":"Front Pharmacol"},{"key":"2026030907401624000_14.3.e012783.5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310835","article-title":"Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer","volume":"24","author":"Garcia-Mouronte","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026030907401624000_14.3.e012783.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1443"},{"key":"2026030907401624000_14.3.e012783.7","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/acs.bioconjchem.5b00302","article-title":"Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity","volume":"26","author":"Gadd","year":"2015","journal-title":"Bioconjugate Chem"},{"key":"2026030907401624000_14.3.e012783.8","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.5"},{"key":"2026030907401624000_14.3.e012783.9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/00498254.2022.2116368","article-title":"A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist","volume":"52","author":"Rynn","year":"2022","journal-title":"Xenobiotica"},{"key":"2026030907401624000_14.3.e012783.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026030907401624000_14.3.e012783.11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3903"},{"key":"2026030907401624000_14.3.e012783.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219517","article-title":"Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy","volume":"14","author":"Hage","year":"2019","journal-title":"PLoS One"},{"key":"2026030907401624000_14.3.e012783.13","doi-asserted-by":"crossref","first-page":"112055","DOI":"10.1016\/j.intimp.2024.112055","article-title":"CD300e: Emerging role and mechanism as an immune-activating receptor","volume":"133","author":"Liu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026030907401624000_14.3.e012783.14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026030907401624000_14.3.e012783.15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1683347","article-title":"The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia","volume":"9","author":"Xu","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026030907401624000_14.3.e012783.16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41392-020-00356-8","article-title":"TREM2 marks tumor-associated macrophages","volume":"5","author":"Nakamura","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"2026030907401624000_14.3.e012783.17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155497","article-title":"Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases","volume":"21","author":"Skytthe","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026030907401624000_14.3.e012783.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1572"},{"key":"2026030907401624000_14.3.e012783.19","first-page":"1085","article-title":"Modes of action of TLR7 agonists in cancer therapy","volume":"6","author":"Kobold","year":"2014","journal-title":"Immunotherapy (Los Angel)"},{"key":"2026030907401624000_14.3.e012783.20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"Npj Precis Onc"},{"key":"2026030907401624000_14.3.e012783.21","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"MAbs"},{"key":"2026030907401624000_14.3.e012783.22","doi-asserted-by":"crossref","unstructured":"Miller A , Le T , Holland J , et al . 1167 APR003, an oral liver- and GI-targeted TLR7 agonist, elicits a robust type I interferon response in advanced colorectal cancer patients. Regular and young investigator award abstracts, BMJ Publishing Group Ltd, A1210; 2022","DOI":"10.1136\/jitc-2022-SITC2022.1167"},{"key":"2026030907401624000_14.3.e012783.23","first-page":"1477","article-title":"Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study","volume":"10","author":"Wang","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2026030907401624000_14.3.e012783.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2026030907401624000_14.3.e012783.25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA768","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study","volume":"42","author":"Andre","year":"2024","journal-title":"JCO"},{"key":"2026030907401624000_14.3.e012783.26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW","volume":"42","author":"Galle","year":"2024","journal-title":"JCO"},{"key":"2026030907401624000_14.3.e012783.27","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"2026030907401624000_14.3.e012783.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2026030907401624000_14.3.e012783.29","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(21)01279-9","article-title":"Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed\/Refractory (R\/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)","volume":"21","author":"Carlo-Stella","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026030907401624000_14.3.e012783.30","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026030907401624000_14.3.e012783.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00694-4"},{"key":"2026030907401624000_14.3.e012783.32","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.21"},{"key":"2026030907401624000_14.3.e012783.33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026030907401624000_14.3.e012783.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02824-y"},{"key":"2026030907401624000_14.3.e012783.35","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2023.41.16_suppl.2538","article-title":"A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"JCO"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:40:29Z","timestamp":1773067229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-012783"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012783","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}